TW201713323A - Therapeutic compositions and methods of use thereof - Google Patents

Therapeutic compositions and methods of use thereof

Info

Publication number
TW201713323A
TW201713323A TW105112404A TW105112404A TW201713323A TW 201713323 A TW201713323 A TW 201713323A TW 105112404 A TW105112404 A TW 105112404A TW 105112404 A TW105112404 A TW 105112404A TW 201713323 A TW201713323 A TW 201713323A
Authority
TW
Taiwan
Prior art keywords
methods
therapeutic compositions
component
human
agents
Prior art date
Application number
TW105112404A
Other languages
English (en)
Chinese (zh)
Inventor
Gene H Zaid
Thomas W Burgoyne
Original Assignee
Ions Pharmaceutical S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/721,011 external-priority patent/US9402834B2/en
Priority claimed from PCT/US2015/055968 external-priority patent/WO2016064676A1/fr
Application filed by Ions Pharmaceutical S A R L filed Critical Ions Pharmaceutical S A R L
Publication of TW201713323A publication Critical patent/TW201713323A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105112404A 2015-05-13 2016-04-21 Therapeutic compositions and methods of use thereof TW201713323A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562161090P 2015-05-13 2015-05-13
US14/721,011 US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
US201562184051P 2015-06-24 2015-06-24
PCT/US2015/055968 WO2016064676A1 (fr) 2014-10-21 2015-10-16 Agents thérapeutiques humains

Publications (1)

Publication Number Publication Date
TW201713323A true TW201713323A (en) 2017-04-16

Family

ID=57248993

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105112404A TW201713323A (en) 2015-05-13 2016-04-21 Therapeutic compositions and methods of use thereof

Country Status (2)

Country Link
TW (1) TW201713323A (fr)
WO (1) WO2016181220A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI798994B (zh) * 2020-12-17 2023-04-11 中國醫藥大學 醫藥組合物治療肺癌之用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN114671779B (zh) * 2022-03-15 2023-08-22 温州医科大学 含环戊酮片段的化合物及其作为抗肿瘤药物的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869540B1 (fr) * 2004-04-30 2008-05-16 Centre Nat Rech Scient Cnrse Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
CN100553628C (zh) * 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
WO2008150899A1 (fr) * 2007-05-29 2008-12-11 Emory University Thérapies combinées pour le traitement du cancer et des maladies inflammatoires
US20130231360A1 (en) * 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
US20120058208A1 (en) * 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
US8039025B1 (en) 2010-10-15 2011-10-18 Life Plus, LLC Methods and dosage forms for the treatment of human cancers
WO2015006646A1 (fr) * 2013-07-11 2015-01-15 Specialty Nutrition Group, Inc. Compositions comprenant un hydroxytyrosol, une curcumine, et/ou astaxanthine et leur utilisation
ES2744913T3 (es) * 2014-10-21 2020-02-26 Ankh Life Sciences Ltd Agentes terapéuticos humanos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI798994B (zh) * 2020-12-17 2023-04-11 中國醫藥大學 醫藥組合物治療肺癌之用途

Also Published As

Publication number Publication date
WO2016181220A3 (fr) 2016-12-29
WO2016181220A2 (fr) 2016-11-17

Similar Documents

Publication Publication Date Title
MX2017002489A (es) Agentes terapeuticos humanos.
MY187540A (en) Compounds active towards bromodomains
GB2541571A (en) Pharmaceutical compositions
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3250589A4 (fr) Agents diagnostiques et thérapeutiques
TN2017000074A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
TW201713323A (en) Therapeutic compositions and methods of use thereof
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IL271327A (en) Compositions and methods for enhancing hyperthermic therapy
PH12016501838A1 (en) Compounds and their methods of use
EP3413906A4 (fr) Compositions de combinaison de traitement du cancer, procédés et utilisations
IL273470A (en) Semaglutide in medical treatment
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
HK1258999A1 (zh) 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物
EP3302530A4 (fr) Agents thérapeutiques à base de cdh26 et leur utilisation
IL269121A (en) Usl-311 for use in the treatment of cancer
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
PH12017501979A1 (en) Pharmaceutical compound
GB2539742B (en) Therapeutic treatment methods, and apparatus for use therein
IL255168A0 (en) Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer
IL274866A (en) Preparations and methods for the treatment of cancer